August 2020

ISOPP Members, the seventy-fourth issue of the Virtual Journal Club (VJC) is available on the International Society of Oncology Pharmacy Practitioners (ISOPP) website. To access it, visit the https://www.isopp.org/isopp-education-resources/virtual-journal-club-surveys 

 

Please share your comments, reflections, suggestions, concerns, tips, agreements or non-agreements with us via email at standards@isopp.org, prior to August 29, 2020.

www.isopp.org/isopp-education-resources/members-only#member-standards 

 

Have you yet checked out ISOPP’s Biosimilars Toolkit of Resources that was launched in May 2020?  Let us know your feedback and give us your ideas for more resources by emailing services@isopp.org.

The Toolkit provides tools aimed at assisting oncology pharmacy practitioners to understand and implement Biosimilars in their practice. It forms part of ISOPP’s Virtual Library and access is complimentary for members.  Not a member?  Join ISOPP.

 

ISOPP Members, the ISOPP quarterly Newsletter was distributed to your inbox today. Read about updates and other important news from ISOPP and members around the world!

 

The COVID-19 pandemic predictably put the activities of many organizations involved in international health either on temporary hold or re-focused on more immediate health care systems/facility planning for patients with and without malignant disease. The activity of the WHO Essential Medicines List (EML) Secretariat were one of those notably affected.  Now that the pandemic is (albeit far from over) slowly coming under control, some of these activities are re-initiating.  ISOPP (via this Task Force) has been recently invited to participate in a number of these activities.  

 

ISOPP has been invited to collaborate in the creation of the Handbook, which as a first step, will commence with generation of an initial set of 4 of these Treatment Regimens.  What WHO is asking for from ISOPP is to provide feedback from the point of view of an Oncology Pharmacist on the feasibility/practicality/challenges and pitfalls of implementing and delivering these chemotherapy regimens in the Low and Middle Income Country (LMIC) context.